EXEL

Exelixis Inc

Add to Watchlist

Advanced Chart

45.600

+0.81(1.808%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

45.720

Open

45.210

VWAP

45.40

Vol

3.57M

Mkt Cap

12.44B

Low

44.830

Amount

162.22M

EV/EBITDA(TTM)

13.51

Total Shares

291.29M

11.40B

EV/OCF(TTM)

13.53

P/S(TTM)

5.79

Exelixis, Inc. is an oncology company. The Company has produced four marketed pharmaceutical products, two of which are formulations of its flagship molecule, cabozantinib. It is also advancing and evolving its product pipeline portfolio, including its lead investigational asset, zanzalintinib. Cabozantinib is an inhibitor of multiple tyrosine kinases, including MET, AXL, VEGF receptors and RET and has been also approved as CABOMETYX tablets for advanced renal cell carcinoma, for previously treated hepatocellular carcinoma and for previously treated, radioactive iodine-refractory differentiated thyroid cancer, and as COMETRIQ capsules for progressive, metastatic medullary thyroid cancer. The Company's other two products are COTELLIC, an inhibitor of MEK approved as part of multiple combination regimens to treat specific forms of advanced melanoma and MINNEBRO an oral, non-steroidal, selective blocker of the mineralocorticoid receptor approved the treatment of hypertension in Japan.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2025Q3

FY2025Q2

608.94M

+7.44%

592.78M

+9.87%

574.36M

-9.86%

Estimates Revision

The market is revising Upward the revenue expectations for Exelixis, Inc. (EXEL) for FY2025, with the revenue forecasts being adjusted by 3.88% over the past three months. During the same period, the stock price has changed by 18.63%.

Revenue Estimates for FY2025

Revise Upward

+3.88%

In Past 3 Month

Stock Price

Go Up

+18.63%

In Past 3 Month

18 Analyst Rating

-0.77% Downside

Wall Street analysts forecast EXEL stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for EXEL is 45.25 USD with a low forecast of 29.00 USD and a high forecast of 60.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

11 Buy

7 Hold

0 Sell

Moderate Buy

-0.77% Downside

Current: 45.600

Low

29.00

Averages

45.25

High

60.00

-0.77% Downside

Current: 45.600

Low

29.00

Averages

45.25

High

60.00

Morgan Stanley

Sean Laaman

Overweight

maintain

$47 -> $48

2025-07-22

Reason

Morgan Stanley

Sean Laaman

Price Target

$47 -> $48

2025-07-22

maintain

Overweight

Reason

Morgan Stanley analyst Sean Laaman raised the firm's price target on Exelixis to $48 from $47 and keeps an Overweight rating on the shares. The firm, which made model updates ahead of Q2 earnings due on Monday, July 28, and noted that its FY25 net product revenue estimate slightly increased to $2.105B, is watching for Zanza Phase 3 data in the second half.

Truist

Asthika Goonewardene

Buy

maintain

$55 -> $56

2025-07-15

Reason

Truist

Asthika Goonewardene

Price Target

$55 -> $56

2025-07-15

maintain

Buy

Reason

Truist analyst Asthika Goonewardene raised the firm's price target on Exelixis to $56 from $55 and keeps a Buy rating on the shares. The stock's recent outperformance spurred some investor questions whether the stock was now overvalued, but the firm believes that shares have more room to run, the analyst tells investors in a research note. Credit needs to be given where due - in particular given that its legacy drug Cabometyx is still poised for robust growth - while the company's next-gen drug Zanza begin launches in 2026 and has a clear path to the $5B revenue target through the 6 indications currently being pursued, the firm added.

UBS

Ashwani Verma

Neutral

maintain

$38 -> $43

2025-07-11

Reason

UBS

Ashwani Verma

Price Target

$38 -> $43

2025-07-11

maintain

Neutral

Reason

UBS analyst Ashwani Verma raised the firm's price target on Exelixis to $43 from $38 and keeps a Neutral rating on the shares.

Barclays

Equal Weight

maintain

$29 -> $40

2025-07-10

Reason

Barclays

Price Target

$29 -> $40

2025-07-10

maintain

Equal Weight

Reason

Barclays raised the firm's price target on Exelixis to $40 from $29 and keeps an Equal Weight rating on the shares. The firm updated the company's model to reflect a higher probability of sucess in colorectal cancer.

RBC Capital

Outperform

Sector Perform

downgrade

$45 -> $50

2025-07-08

Reason

RBC Capital

Price Target

$45 -> $50

2025-07-08

downgrade

Outperform

Sector Perform

Reason

RBC Capital downgraded Exelixis to Sector Perform from Outperform with a price target of $50, up from $45.

RBC Capital

Leonid Timashev

Outperform -> Sector Perform

downgrade

$45 -> $50

2025-07-08

Reason

RBC Capital

Leonid Timashev

Price Target

$45 -> $50

2025-07-08

downgrade

Outperform -> Sector Perform

Reason

RBC Capital analyst Leonid Timashev downgraded Exelixis to Sector Perform from Outperform with a price target of $50, up from $45. The firm believes the shares at current levels are fairly valuing the remaining branded Cabometyx cash flows and probability weighted life-cycle potential ahead of the 2031 patent cliff. RBC wants to see additional life cycle success that can offset the loss of Cabometyx before again recommending shares of Exelixis.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Exelixis Inc (EXEL.O) is 19.59, compared to its 5-year average forward P/E of 32.16. For a more detailed relative valuation and DCF analysis to assess Exelixis Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

Fair

5Y Average PE

32.16

Current PE

19.59

Overvalued PE

49.72

Undervalued PE

14.60

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Fair

5Y Average EV/EBITDA

19.06

Current EV/EBITDA

12.53

Overvalued EV/EBITDA

30.14

Undervalued EV/EBITDA

7.98

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Overvalued

5Y Average PS

4.12

Current PS

5.17

Overvalued PS

5.15

Undervalued PS

3.09

Financials

Annual

Quarterly

FY2025Q1

YoY :

+30.62%

555.45M

Total Revenue

FY2025Q1

YoY :

+199.95%

186.86M

Operating Profit

FY2025Q1

YoY :

+327.73%

159.62M

Net Income after Tax

FY2025Q1

YoY :

+358.33%

0.55

EPS - Diluted

FY2025Q1

YoY :

+252.58%

208.49M

Free Cash Flow

FY2025Q1

YoY :

+1.63%

96.55

Gross Profit Margin - %

FY2025Q1

YoY :

+135.87%

35.71

FCF Margin - %

FY2025Q1

YoY :

+227.33%

28.74

Net Margin - %

FY2025Q1

YoY :

+244.98%

30.22

ROIC

Trading Trends

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

21.0M

USD

3-6

Months

11.1M

USD

6-9

Months

10.1M

USD

0-12

Months

3.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Hedge Fund

Hedge Funds are Neutral. There are no significant trading trends over the last quarter.

Sold

0-3

Months

0.0

Volume

3-6

Months

4.2K

Volume

6-9

Months

0.0

Volume

0-12

Months

0.0

Volume

Bought

0-3

0.0

Volume

Months

3-6

0.0

Volume

Months

6-9

69.6K

Volume

Months

0-12

0.0

Volume

Months

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

0.0

USD

3-6

Months

0.0

USD

6-9

Months

0.0

USD

0-12

Months

0.0

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

Insider

Insiders are Neutral. There are no significant trading trends over the last month.

Sold

0-3

Months

21.0M

USD

3-6

Months

11.1M

USD

6-9

Months

10.1M

USD

0-12

Months

3.6M

USD

Bought

0-3

0.0

USD

Months

3-6

0.0

USD

Months

6-9

0.0

USD

Months

0-12

0.0

USD

Months

EXEL News & Events

Events Timeline

2025-06-23 (ET)

2025-06-23

06:52:49

More data needed to determine Exelixis' competitive positioning, says BofA

2025-06-22 (ET)

2025-06-22

17:50:06

Exelixis announces 'positive' results from STELLAR-303 phase 3 trial

2025-06-20 (ET)

2025-06-20

06:57:16

Exelixis says Ipsen receives positive CHMP opinion for Cabometyx

News

3.0

07-25SeekingAlpha

Exelixis Q2 2025 Earnings Preview

9.0

07-24Newsfilter

Exelixis' Partner Ipsen Receives European Commission Approval for CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors

8.0

07-23NASDAQ.COM

Noteworthy Wednesday Option Activity: GLW, VITL, EXEL